Literature DB >> 572372

The effects of ovariectomy and estrogen treatment on the dopamine inhibition of gonadotropin and prolactin release.

S J Judd, L A Rigg, S S Yen.   

Abstract

The suppressive action of dopamine (DA) on circulating gonadotropin and PRL levels is found to be positively correlated with their basal serum concentrations. Thus, DA inhibition is greater in ovariectomized (agonadal) women than in normal women on day 2 of their menstrual cycles, and the reverse is observed for PRL. Pretreatment of agonadal subjects with estrogen lowers the basal levels of LH and FSH and thereby proportionately decreases the suppressive effects of DA. Estrogen treatment elevates the basal level of PRL in agonadal subjects and also the PRL-inhibiting effect of DA. These findings indicate that castration and estrogen treatment significantly influence the inhibitory effect of DA on gonadotropin and PRL release.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 572372     DOI: 10.1210/jcem-49-2-182

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.

Authors:  G M Prelević; M I Würzburger; L A Perić
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

Review 2.  Control of prolactin secretion.

Authors:  G Benker; C Jaspers; G Häusler; D Reinwein
Journal:  Klin Wochenschr       Date:  1990-12-04

3.  Dopamine decreases release of luteinizing hormone releasing hormone from superfused rat mediobasal hypothalamus.

Authors:  K Tasaka; A Miyake; T Sakumoto; T Aono
Journal:  J Endocrinol Invest       Date:  1985-08       Impact factor: 4.256

4.  Amplification of LH response to LHRH by dopamine infusion in eugonadal women.

Authors:  E Pucci; F Franchi; P M Kicovic; R Sgrilli; D Barletta; G F Argenio; M Gasperi; G P Bernini; M Luisi
Journal:  J Endocrinol Invest       Date:  1981 Jan-Mar       Impact factor: 4.256

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.